Suchen
Connect Biopharma Holdings Ltd
CNTBZur Watchlist hinzufügen
1.070USD
0.0000.00%
Handelsschluss 09-23 16:00（ET）
59.62MMarktkapitalisierung
VerlustKGV TTM
Vorbörsliches Trading 08:14 (ET)1.095USD+0.025+2.34%
Vorbörsliches Trading 08:14 (ET)Über Connect Biopharma Holdings Ltd Unternehmen
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd Profil
BörsenkürzelCNTB
Name des UnternehmensConnect Biopharma Holdings Ltd
IPO-datumMar 19, 2021
CEOQuart (Barry D)
Anzahl der mitarbeiter62
WertpapierartOrdinary Share
GeschäftsjahresendeMar 19
Addresse3580 Carmel Mountain Road, Suite 200
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92130
Telefon18587271040
Websitehttps://www.connectbiopharm.com
BörsenkürzelCNTB
IPO-datumMar 19, 2021
CEOQuart (Barry D)
Führungskräfte von Connect Biopharma Holdings Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
11.78K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Connect Biopharma Holdings Ltd?
Die fünf größten Anteilseigner von Connect Biopharma Holdings Ltd sind: Dr. Barry D. Quart, Pharm.D.
Wie viele Institutionen halten Anteile an Connect Biopharma Holdings Ltd (CNTB)?
Mit Stand vom 2026Q1 halten 51 Institutionen Anteile an Connect Biopharma Holdings Ltd, mit einem Gesamtmarktwert von etwa 29.94M, was 52.97% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 8109973.00 gestiegen.